Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
Type:
Grant
Filed:
March 30, 2006
Date of Patent:
April 14, 2009
Assignee:
Bayer Healthcare LLC
Inventors:
Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
Type:
Grant
Filed:
April 12, 2006
Date of Patent:
March 31, 2009
Assignee:
Bayer HealthCare LLC
Inventors:
Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.
Type:
Grant
Filed:
August 14, 2006
Date of Patent:
October 7, 2008
Assignee:
Bayer HealthCare LLC
Inventors:
Clark Pan, Andreas M. Knorr, Michael Schauer, Claudia Hirth-Dietrich, Sabine Kraft, Barbara Krebs
Abstract: The invention relates to novel 1-aza-bicyclic N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
Type:
Grant
Filed:
March 3, 2003
Date of Patent:
November 21, 2006
Assignee:
Bayer HealthCare AG
Inventors:
Joachim Luithle, Frank-Gerhard Böss, Christina Erb, Katrin Schnizler, Timo Flessner, Marja van Kampen, Christoph Methfessel, Frank-Thorsten Hafner
Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
Type:
Grant
Filed:
August 20, 2004
Date of Patent:
October 17, 2006
Assignee:
Bayer HealthCare AG
Inventors:
Maria Niewöhner, legal representative, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Semo, Marc Nowakowski, Ulrich Niewöhner, deceased
Abstract: This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.
Type:
Grant
Filed:
September 22, 2004
Date of Patent:
September 26, 2006
Assignee:
Bayer Pharmaceuticals Corporation
Inventors:
Derek B. Lowe, Philip L. Wickens, Xin Ma, Mingbao Zhang, William H. Bullock, Philip D. G. Coish, Ingo Mugge, Andreas Stolle, Ming Wang, Yamin Wang, Chengzhi Zhang, Hai-Jun Zhang, Lei Zhu, Manami Tsutsumi, James N. Livingston
Abstract: The present invention relates to a solid dispersion of quinolone- or naphthyridonecarboxylic acids in an insoluble matrix representative of a shellac, and methods preparing and using the same in masking the taste and improving the uptake by animals.
Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
Type:
Grant
Filed:
April 28, 2004
Date of Patent:
September 19, 2006
Assignee:
Bayer Pharmaceuticals Corporation
Inventors:
Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sidney X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi
Abstract: Novel imidazotriazinones of general formula a method for the production and the pharmaceutical use thereof are disclosed.
Type:
Grant
Filed:
January 5, 2005
Date of Patent:
August 29, 2006
Assignee:
Bayer Pharmaceuticals Corporation
Inventors:
Maria Niewohner, legal representative, Mazen Es-Sayed, Thomas Lampe, Helmut Haning, Gunter Schmidt, Karl-Heinz Schlemmer, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn, Ulrich Niewohner, deceased
Abstract: The invention relates to imidazo[1,3,5]triazinones, a method for their production and methods of use, in particular as inhibitors of cyclic GMP metabolizing phosphodiesterases.
Type:
Grant
Filed:
July 15, 2004
Date of Patent:
August 15, 2006
Assignee:
Bayer Healthcare AG
Inventors:
Ulrich Niewöhner, Helmut Haning, Thomas Lampe, Mazen Es-Sayed, Gunter Schmidt, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn, Karl-Heinz Schlemmer
Abstract: The present invention relates to novel 2,5-disubstituted pyrimidine derivatives which stimulate soluble guanylate cyclase, to processes for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of central nervous system diseases.
Type:
Grant
Filed:
July 7, 2003
Date of Patent:
August 15, 2006
Assignee:
Bayer HealthCare AG
Inventors:
Achim Feurer, Joachim Luithle, Stephan-Nicholas Wirtz, Gerhard König, Johannes-Peter Stasch, Elke Stahl, Rudy Schreiber, Frank Wunder
Abstract: This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.
Type:
Grant
Filed:
May 6, 2004
Date of Patent:
August 15, 2006
Assignee:
Bayer Pharmaceuticals Corporation
Inventors:
Roger Smith, Ann-Marie Campbell, Philip Coish, Miao Dai, Susan Jenkins, Derek Lowe, Stephen O'Connor, Ning Su, Gan Wang, Mingbao Zhang, Lei Zhu
Abstract: This invention relates to 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.
Type:
Grant
Filed:
September 24, 2002
Date of Patent:
July 4, 2006
Assignee:
Bayer Pharmaceuticals Corporation
Inventors:
Roger A. Smith, Stephen J. O'Connor, Wai C. Wong, Soongyu Choi, Harold C. Kluender, Jianmei Fan, Zhonghua Zhang, Rico C. Lavoie, Brent L. Podlogar
Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
Type:
Grant
Filed:
January 16, 2003
Date of Patent:
May 9, 2006
Assignee:
Bayer Pharmaceuticals Corporation
Inventors:
Clark Pan, James Whelan, Kevin B. Clairmont
Abstract: The invention relates to novel substituted imidazotriazinones, to a method for their production and to the use thereof for producing medicaments, in particular to improve perception, powers of concentration, learning capacity and/or memory retentiveness.
Type:
Grant
Filed:
February 11, 2002
Date of Patent:
February 14, 2006
Assignee:
Bayer Aktiengesellschaft
Inventors:
Maria Theresia Niewöhner, legal representative, Dagmar Schauss, Gerhard König, Martin Hendrix, Frank-Gerhard Böss, Franz-Josef van der Staay, Rudy Schreiber, Karl-Heinz Schlemmer, Toshiya Moriwaki, Ulrich Niewöhner, deceased
Abstract: The present invention relates to a process for the preparation of sulphonamide-substituted imidazotriazinones of the general formula (I) characterized in that compounds of the formula (II) are reacted with sulphuric acid and the products obtained are then reacted with thionyl chloride and converted in situ in an inert solvent using an amine into the compounds according to the invention and, if appropriate, reacted to give the corresponding salts, hydrates or N-oxides.
Type:
Grant
Filed:
May 5, 2005
Date of Patent:
February 14, 2006
Assignee:
Bayer HealthCare Aktiengesellschaft
Inventors:
Marc Nowakowski, Reinhold Gehring, Werner Heilmann, Karl-Heinz Wahl
Abstract: The present invention relates to methods for assessing enzyme activity utilizing a phase partition system. In addition, the present invention also relates to methods for screening and identifying compounds that may be used, for example, for the treatment of diabetes, diabetes-related disorders, obesity, cardiovascular disease, cancer, and other diseases or disorders, using this phase partition system.
Type:
Grant
Filed:
August 4, 2004
Date of Patent:
February 7, 2006
Assignee:
Bayer Pharmaceuticals Corporation
Inventors:
James A. Landro, David G. Osterman, Walter Pickett
Abstract: The present invention relates to a semi-hydrochloride of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline-carboxylic acid, to processes for its preparation and to antibacterial compositions comprising it. The semihydrochloride of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.
Abstract: The present invention relates to FMDC vaccine based on peptides having a sequence of at least 8 amino acids, which corresponds to a partial sequence of the non-structural protein region of FMDV, which was selected by immunoreactivity with FMDV-specific antibodies or by immunoreactivity with FMDV-specific T lymphocytes, and to their production and their use.